Is ProPhase Labs Stock a Good Investment?
ProPhase Labs Investment Advice | PRPH |
- Examine ProPhase Labs' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research ProPhase Labs' leadership team and their track record. Good management can help ProPhase Labs navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact ProPhase Labs' business and its evolving consumer preferences.
- Compare ProPhase Labs' performance and market position to its competitors. Analyze how ProPhase Labs is positioned in terms of product offerings, innovation, and market share.
- Check if ProPhase Labs pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about ProPhase Labs' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in ProPhase Labs stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if ProPhase Labs is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine ProPhase Labs Stock
Researching ProPhase Labs' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 1.07. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. ProPhase Labs recorded a loss per share of 2.23. The entity last dividend was issued on the 24th of May 2022. The firm had 2:1 split on the 23rd of January 1997.
To determine if ProPhase Labs is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ProPhase Labs' research are outlined below:
| ProPhase Labs had very high historical volatility over the last 90 days | |
| ProPhase Labs has some characteristics of a very speculative penny stock | |
| ProPhase Labs has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 6.77 M. Net Loss for the year was (49.52 M) with profit before overhead, payroll, taxes, and interest of 436 K. | |
| ProPhase Labs currently holds about 27.5 M in cash with (17.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from gurufocus.com: ProPhase Labs Announces Closing of 3 Million Senior Secured Convertible Notes Financing PRPH ... |
ProPhase Labs Quarterly Cash And Short Term Investments |
|
ProPhase Labs uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ProPhase Labs. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ProPhase Labs' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact ProPhase Labs' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises ProPhase Labs' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2004-10-28 | 2004-09-30 | 0.02 | 0.03 | 0.01 | 50 | ||
1997-08-13 | 1997-06-30 | 0.08 | 0.07 | -0.01 | 12 | ||
2010-11-10 | 2010-09-30 | 0.09 | 0.06 | -0.03 | 33 | ||
2000-10-26 | 2000-09-30 | -0.02 | 0.01 | 0.03 | 150 | ||
1998-10-30 | 1998-09-30 | 0.23 | 0.2 | -0.03 | 13 | ||
1998-07-31 | 1998-06-30 | -0.04 | 1.0E-4 | 0.0401 | 100 | ||
2025-05-07 | 2025-03-31 | -0.18 | -0.1328 | 0.0472 | 26 | ||
2004-07-30 | 2004-06-30 | -0.03 | -0.08 | -0.05 | 166 |
Know ProPhase Labs' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ProPhase Labs is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ProPhase Labs backward and forwards among themselves. ProPhase Labs' institutional investor refers to the entity that pools money to purchase ProPhase Labs' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Chapin Davis Inc | 2025-06-30 | 80 K | Susquehanna International Group, Llp | 2025-03-31 | 74 K | Blackrock Inc | 2025-03-31 | 68.9 K | Jane Street Group Llc | 2025-03-31 | 48.4 K | Bp Wealth Management, Llc | 2025-03-31 | 47.7 K | State Street Corp | 2025-03-31 | 44.7 K | Bank Of New York Mellon Corp | 2025-03-31 | 37.1 K | United Capital Management Of Ks | 2025-03-31 | 34.7 K | Two Sigma Securities, Llc | 2025-03-31 | 34.4 K | Wexford Capital Lp | 2025-03-31 | 1.5 M | Vanguard Group Inc | 2025-03-31 | 408.3 K |
ProPhase Labs' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 18.07 M.Market Cap |
|
ProPhase Labs' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.11) | (1.05) | |
| Return On Capital Employed | (1.24) | (1.18) | |
| Return On Assets | (0.84) | (0.80) | |
| Return On Equity | (7.26) | (6.89) |
Determining ProPhase Labs' profitability involves analyzing its financial statements and using various financial metrics to determine if ProPhase Labs is a good buy. For example, gross profit margin measures ProPhase Labs' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ProPhase Labs' profitability and make more informed investment decisions.
Evaluate ProPhase Labs' management efficiency
ProPhase Labs has return on total asset (ROA) of (0.3092) % which means that it has lost $0.3092 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.623) %, meaning that it created substantial loss on money invested by shareholders. ProPhase Labs' management efficiency ratios could be used to measure how well ProPhase Labs manages its routine affairs as well as how well it operates its assets and liabilities. The ProPhase Labs' current Return On Tangible Assets is estimated to increase to -1.05. The ProPhase Labs' current Return On Capital Employed is estimated to increase to -1.18. As of now, ProPhase Labs' Intangible Assets are increasing as compared to previous years. The ProPhase Labs' current Other Assets is estimated to increase to about 1.6 M, while Total Assets are projected to decrease to under 36.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.39 | 0.37 | |
| Tangible Book Value Per Share | (0.40) | (0.38) | |
| Enterprise Value Over EBITDA | (1.19) | (1.13) | |
| Price Book Value Ratio | 1.96 | 1.87 | |
| Enterprise Value Multiple | (1.19) | (1.13) | |
| Price Fair Value | 1.96 | 1.87 | |
| Enterprise Value | 44.1 M | 41.9 M |
Effective leadership at ProPhase Labs drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta (0.40) |
Basic technical analysis of ProPhase Stock
As of the 24th of July, ProPhase Labs holds the Semi Deviation of 5.57, coefficient of variation of 745.64, and Risk Adjusted Performance of 0.1279. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of ProPhase Labs, as well as the relationship between them.ProPhase Labs' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProPhase Labs insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProPhase Labs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ProPhase Labs insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ProPhase Labs' Outstanding Corporate Bonds
ProPhase Labs issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ProPhase Labs uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ProPhase bonds can be classified according to their maturity, which is the date when ProPhase Labs has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| US74348YAV39 Corp BondUS74348YAV39 | View | |
| US74348YDX67 Corp BondUS74348YDX67 | View | |
| PROSPECT CAP P Corp BondUS74348YEA55 | View | |
| US74348TAV44 Corp BondUS74348TAV44 | View | |
| PSEC 3437 15 OCT 28 Corp BondUS74348TAW27 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| PROLOGIS L P Corp BondUS74340XBH35 | View |
Understand ProPhase Labs' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing ProPhase Labs' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1279 | |||
| Market Risk Adjusted Performance | 0.3922 | |||
| Mean Deviation | 4.69 | |||
| Semi Deviation | 5.57 | |||
| Downside Deviation | 7.29 | |||
| Coefficient Of Variation | 745.64 | |||
| Standard Deviation | 6.12 | |||
| Variance | 37.51 | |||
| Information Ratio | 0.0989 | |||
| Jensen Alpha | 0.3745 | |||
| Total Risk Alpha | (0.60) | |||
| Sortino Ratio | 0.0831 | |||
| Treynor Ratio | 0.3822 | |||
| Maximum Drawdown | 30.85 | |||
| Value At Risk | (11.90) | |||
| Potential Upside | 10.0 | |||
| Downside Variance | 53.1 | |||
| Semi Variance | 31.01 | |||
| Expected Short fall | (5.98) | |||
| Skewness | (0.47) | |||
| Kurtosis | 0.7167 |
| Risk Adjusted Performance | 0.1279 | |||
| Market Risk Adjusted Performance | 0.3922 | |||
| Mean Deviation | 4.69 | |||
| Semi Deviation | 5.57 | |||
| Downside Deviation | 7.29 | |||
| Coefficient Of Variation | 745.64 | |||
| Standard Deviation | 6.12 | |||
| Variance | 37.51 | |||
| Information Ratio | 0.0989 | |||
| Jensen Alpha | 0.3745 | |||
| Total Risk Alpha | (0.60) | |||
| Sortino Ratio | 0.0831 | |||
| Treynor Ratio | 0.3822 | |||
| Maximum Drawdown | 30.85 | |||
| Value At Risk | (11.90) | |||
| Potential Upside | 10.0 | |||
| Downside Variance | 53.1 | |||
| Semi Variance | 31.01 | |||
| Expected Short fall | (5.98) | |||
| Skewness | (0.47) | |||
| Kurtosis | 0.7167 |
Consider ProPhase Labs' intraday indicators
ProPhase Labs intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ProPhase Labs stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ProPhase Labs time-series forecasting models is one of many ProPhase Labs' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ProPhase Labs' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
ProPhase Stock media impact
There is far too much social signal, news, headlines, and media speculation about ProPhase Labs that are available to investors today. This information is accessible both publicly - through ProPhase Labs' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of ProPhase-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of ProPhase Labs news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ProPhase Labs relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ProPhase Labs' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ProPhase Labs alpha.
ProPhase Labs Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards ProPhase Labs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ProPhase Labs Corporate Management
| Billy White | Consultant | Profile | |
| Lance Bisesar | Corporate Controller | Profile | |
| Robert Morse | Principal Controller | Profile | |
| Stu Hollenshead | Chief Officer | Profile | |
| Sergio Miralles | Executive Diagnostics | Profile | |
| Kamal Obbad | Senior Genomics | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (2.23) | Revenue Per Share | Quarterly Revenue Growth (0.39) | Return On Assets |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between ProPhase Labs' value and its price, as these two are different measures arrived at by various means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.